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Gene-specific expansion of polyglutamine-encoding CAG repeats
can cause neurodegenerative disorders, including Huntington’s
disease. It is believed that part of the pathological effect of the
expanded protein is due to transcriptional dysregulation. Using
Drosophila as a model, we show that cAMP-response element-
binding protein (CREB) is involved in expanded polyglutamine-
induced toxicity. A mutation in the Drosophila homolog of CREB,
dCREB2, enhances lethality due to polyglutamine peptides (polyQ),
and an additional copy of dCREB2 partially rescues this lethality.
Neuronal expression of expanded polyQ attenuates in vivo CRE-
mediated transcription of a reporter gene. As reported previously,
overexpression of heat-shock protein 70 (Hsp70) rescues polyglu-
tamine-dependent lethality. However, it does not rescue CREB-
mediated transcription. The protective effects of CREB and heat-
shock protein 70 against polyQ are additive, suggesting that
targeting multiple pathways may be effective for treatment of
polyglutamine diseases.
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Expansion of polyglutamine-encoding repeats is implicated in theetiology of at least nine neurological disorders (for review, see
ref. 1). It is known that long polyglutamine peptides (polyQ)
themselves are sufficient to induce neurodegeneration (2), suggest-
ing that the naturally occurring expansions cause disease due to a
gain-of-function mechanism. There is evidence that polyQ expan-
sion targets multiple cellular functions, including transcription,
proteasomal degradation, molecular chaperones, and axonal trans-
port (for review, see ref. 3).
For some of these diseases, aspects of the pathology are attrib-
utable to transcriptional dysregulation. Proteins with expanded
polyglutamine stretches can interact with transcriptional cofactors,
and transcription is altered in mouse models or patients with
polyglutamine expansions (for review, see ref. 4). Transcription
cofactors, including cAMP-response element-binding protein-
(CREB) binding protein (CBP) and TAFII130, have been found in
inclusions in cell culture models or patients of polyglutamine
diseases (5–8), and sequestration of these proteins into insoluble
aggregates has been suspected to contribute to transcriptional
dysregulation. It has been reported that polyQ can inhibit the
acetyltransferase activity of CBP (9). Accordingly, inhibition of
histone deacetylase activity (9, 10), or overexpression of CBP (8,
11), can reverse the deleterious effects due to expanded polyQ
proteins.
CREB is one of the transcription factors that interact with
CBP, and it has been implicated in the pathology of polyglu-
tamine diseases. CREB-mediated transcription of reporter
genes is attenuated in cultured cells that transiently express
polyQ (5–8, 12, 13). Many genes regulated by the cAMP
signaling pathway are down-regulated at an early symptomatic
stage in cellular and mouse models of Huntington’s disease (12,
14). Forskolin stimulation of adenylyl cyclase, as well as over-
expression of an activated CREB, ameliorated mutant Hunting-
tin- (htt) induced phenotypes in a cell culture model (7, 12).
Knocking out CREB leads to apoptosis and neurodegeneration
in sensory neurons of genetically modified mice (15). Combining
the knockout with a null mutation in the closely related family
member cAMP-response element modulator (CREM) leads to
mice with atrophy of the hippocampus and striatum, a phenotype
reminiscent of Huntington’s disease patients (16). The levels of
cAMP and phosphorylation of CREB decrease in a mouse
model with mutant htt that contains 111 glutamine residues (17).
However, a recent report shows that phosphorylation of CREB,
as well as CRE reporter activity, is enhanced in a transgenic
mouse harboring a mutant exon 1 of human htt, suggesting that
the role of CREB in polyQ pathology is still unclear (18).
Drosophila models of polyQ diseases have successfully recapitu-
lated some of the pathological features seen in human diseases,
including formation of inclusions, cell degeneration, motor dys-
function, and premature death (2, 9, 11, 19–23). In this report, we
use the Gal4upstream activating sequence (UAS) expression
system to overexpress polyQ in neurons (2, 9) and test for genetic
interaction between polyQ-mediated toxicity and CREB.We dem-
onstrate that amutation in dCREB2 enhances the lethality of polyQ
expressed in the nervous system, whereas an additional copy of
dCREB2 partially rescues polyQ-induced lethality. Expression of
polyQ in neurons attenuates CRE-mediated reporter activity in
vivo. PKA, which increases CREB activity, rescues polyQ-induced
lethality as well.
In addition to the restoration of transcriptional activity (4, 9–12),
it has been reported that overexpression or activation of molecular
chaperones can rescue polyQ-induced toxicity, presumably by in-
creasing solubility of polyQproteins (21, 24–33).We testedwhether
the protective effect of the molecular chaperone, heat-shock
protein 70 (Hsp70), affected CREB activity. We found that over-
expression of Hsp70 rescues polyQ-mediated lethality without
recovery of CREB activity, and that the protective effects of CREB
and Hsp70 against polyQ are additive.
Materials and Methods
Fly Stocks. gmr-Gal4, elav-Gal4, and S162 flies were obtained from
the Bloomington Stock Center, Indiana University. The UAS-
polyglutamine lines were gifts from L. M. Thompson and J. L.
Marsh (2, 9). A genomic fragment carrying the dCREB2 region was
cloned and injected to establish the gdCREB fly lines. A stop codon
was engineered into the coding region of the dCREB2 genomic
fragment, producing the gdCREB stop transgene. The R4F CA-
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MEK1 (N3S218ES222D) cDNA (34), a gift from N. G. Ahn,
was subcloned and used to establish hs-MEK transgenic flies
[hs-MEK, the constitutively active form of mitogen-activated pro-
tein kinase kinase (MEK) under the control of the heat-shock
promoter]. The transgenic flies carrying the CRE-luciferase re-
porter (CRE-Luc) transgene have been described (35). Transgenic
flies carrying the UAS-hsp70 transgene were a gift from N. M.
Bonini (University of Pennsylvania, Philadelphia) (27), and the
hs-PKA* flies (the constitutively active form of PKA) were fromG.
Struhl (Columbia University, New York) (36).
Survival Assay.Fies carrying anUAS transgene in trans to a balancer
chromosome were crossed to flies carrying the GAL4 transgene.
The flies that emerged were collected, and the number of flies with
each genotype was counted. The survival rate was calculated by
dividing the number of polyQ-expressing flies (flies carrying both
the Gal4 and UAS chromosomes, experimental group) by the
number that do not express polyQ (control group) and multiplying
by 100.More than 200 control flies for each genotypewere counted.
Experimentswere repeated three times, and representative data are
shown. The genotypes for all crosses are provided in Supporting
Text, which is published as supporting information on the PNAS
web site. For analysis, we used the 2 test, which approximates how
observed data relate to the expected outcome of the experiment.
The observed data are the number of flies that survive to the adult
stage, and the expected outcome is predicted by the number of flies
with balancer and Mendelian ratio (37).
Antibodies. Anti-dCREB2 monoclonal and Ser-231 phospho-
specific anti-pCREB rabbit polyclonal antibodies have been
described (38).
Luciferase Assay. Flies were raised in a 12:12 lightdark cycle at
25°C. For in vitro assays (Fig. 2 A and B), 5–10 fly heads carrying
CRE-Luc were homogenized and analyzed by using the Luciferase
Assay System (Promega). Luciferase signals were normalized to
total protein concentration. Samples were measured in triplicate,
and two independent determinations were made. In vivo luciferase
activity was recorded from behaving flies as described (35). Briefly,
flies carrying CRE-Luc were loaded in 96-well plates filled with
agar containing sucrose and luciferin (Biosynth, Basel), covered
with PCR caps and clear plastic covers (Topseal, PerkinElmer) that
had holes punched in them. Activity was measured by using a
Topcount microplate scintillation and luminescence counter
(PerkinElmer) under a 12:12 lightdark cycle. For heat-shock
induction ofMEK, flies were raised at 22°C and received heat shock
at 35°C for 30 min per day for 3 days before assaying for luciferase
activity at 25°C. Averages from 20 flies are shown.
Climbing Assay. The climbing assay was performed as described
(39), with slight modifications. Twenty flies were placed in a plastic
vial and gently tapped to the bottom. The number of flies that
reached the top of the vials within 18 sec was counted. The mean
of 20 trials with SEM is shown. The experiments were repeated
independently three times, and similar results were obtained for
each replicate.
Fig. 1. Genetic interaction between CREB and expanded polyQ. (A) S162 is a mutation in dCREB2. (Left) Cartoon of a 9-kb dCREB2 genomic rescue fragment,
showing the coding (gray), alternatively spliced (black), noncoding (white) exons, the translation start (ATG) and engineered stop codon (stop), and the 5 and
3 regions. (Right) Crossing S162FM7 females to transgenic males homozygous for two independent gdCREB insertions (gdCREB#1 and gdCREB#2) but not to
those containing the gdCREBstop transgene (stop) results in rescue of S162 males. The number of progeny for each genotype is shown. (B) S162 increases
polyQ-mediated lethality. The gene dosage of dCREB2 is indicated in the bars. The percent of survivors is calculated by dividing the number of polyQ progeny
flies by the number of expected progeny of each genotype. Two independent UAS-polyQ48 lines (polyQ#13 and polyQ#36) behaved identically. (C)
PolyQ-mediated lethality is sensitive todCREB2gene dosage. Survival rates of flies containing one (S162polyQ), two (polyQ, or gdCREBS162polyQ), or three
copies of genomicdCREB2 (gdCREBpolyQ).dCREB2partially rescues lethality (significant difference between gdCREBpolyQ and polyQ,P0.05,2 value 4.19,
asterisk). Significant differences between S162polyQ and polyQ (P 0.00001, 2 value 27.3) or S162polyQ and gdCREBS162polyQ (P 0.00001, 2 value
46.5) (D) A genomic fragment of dCREB2 with a stop codon (stop) does not alter the survival rate of polyQ-mediated lethality. The survival of polyQ flies was
not different from that of stoppolyQ flies (P 0.05, 2 value 1.09). The stopS162polyQ flies did not survive, similar to the S162polyQ flies, but unlike flies
with two functional copies (C, gdCREBS162polyQ).
10262  www.pnas.orgcgidoi10.1073pnas.0503937102 Iijima-Ando et al.
Results
The Gene Dosage of dCREB2 Modifies PolyQ-Induced Lethality. S162
is an X-linked, homozygous lethal mutation in the Drosophila
dCREB2 gene (35). This mutation is recessive, because the het-
erozygous mutation does not affect the survival rate (see below).
We confirmed that S162 is amutation in the dCREB2 gene by using
genomic rescue. A transgenic copy of the dCREB2 genomic frag-
ment (gdCREB), but not one engineered to contain a stop codon
(stop), rescues viability (Fig. 1A).
In the fly model for polyQ-mediated toxicity, various length
polyQ (Q22, Q48, andQ108) can be placed under the control of the
UAS promoter sequence (2, 9). Elav-Gal4-restricted expression of
Q48 or Q108, but not Q22, in postmitotic neurons results in partial
lethality (9). We find that the survival rate of flies expressing Q48
in the nervous system is sensitive to the gene dosage of the dCREB2
gene. S162 heterozygous flies show twice the polyQ-mediated
lethality as wild-type flies (Fig. 1B). A single copy of S162 itself does
not cause any lethality (S162 divided by FM7 yields 102.8%).
This effect is seen with two independent insertions of the polyQ
transgene, making it unlikely that the increased lethality is due to
the insertion site of either transgene (Fig. 1B). The S162 heterozy-
gous mutation also enhances Q108-mediated lethality (data not
shown). This increase in lethality requires the toxic form of polyQ,
because Q22 expressed in neurons does not show any increase in
toxicity when placed in a heterozygous S162 background (101% for
both wild-type and heterozygous strains). This result demonstrates
that S162’s effect on lethality is specific to toxicity induced through
expanded polyQ.
The enhancement of polyglutamine-induced lethality seen in
heterozygous S162poly Q flies is suppressed when the gdCREB
transgene, but not the stop transgene, is added back (Fig. 1 C and
D). This indicates that the enhancement of lethality due to ex-
panded polyQ is attributable to a loss of dCREB2 function. The
gdCREB transgene, when present as a third genomic copy, also
partially, but significantly, ameliorates the lethality of polyQ flies
(Fig. 1C). Therefore, dCREB2 is sufficient to overcome a signifi-
cant fraction of polyQ-mediated effects because, depending upon
its copy number, it can increase or decrease toxicity.
PolyQ Attenuate CRE-Luc Activity in Vivo. CREB-dependent tran-
scription in vivo can be monitored by using transgenic flies that
contain a CRE-Luc (35). Hemizygous S162 ‘‘escaper’’ flies show a
dramatic decrease in luciferase activity (Fig. 2A), confirming
dCREB2 responsiveness of the reporter (35). When expanded
polyQ is expressed pan-neuronally (using an elav-Gal4 driver) or in
the eye (using gmr-Gal4), luciferase activity measured biochemi-
cally also decreases when compared with control flies (Fig. 2B).
As described (35), dCREB2 activity oscillates in a circadian
manner. Luciferase activity in flies with polyQ108 expression still
cycles but is lower at all time points (Fig. 2D). The short polyQ
(Q22), which does not cause toxicity, also does not attenuateCREB
activity (Fig. 2E). Therefore, the attenuation of CRE-Luc activity
depends on the length of the polyQ tract that is overexpressed and
correlates with toxicity effects of the peptides. However, the
reduction ofCRE-Luc activity is not due to extreme loss of neurons,
because there is little change in the protein level of dCREB2 (Fig.
Fig. 2. Expanded polyQ peptides attenuate CREB-mediated transcription. (A) The CRE-Luc activity in wild-type flies is set to 1 for A and B, and mutants are
normalized to this value. CRE-Luc in S162 hemizygous flies (S162 CRE-Luc) is lower than in control (CRE-Luc) flies (n 5). (B) Expanded polyQ dampens CRE-Luc
activity. CRE-Luc activity in flies expressing Q108 in the nervous system (using elav-GAL4 driver, gray bars) or in the eyes (using gmr-GAL4, black bars) is lower
than in wild-type (CRE-Luc) flies. Flies were collected at Zeitgeber time 2.5. Two independent lines carrying the UAS-polyQ108 transgene (#16 and #2) behaved
identically. (C) PolyQ does not affect Ser-231 phosphorylation. Western blot of aliquots of the sample used inBprobed with anti-dCREB2 (CREB) or anti-dCREB2-P,
a phosphospecific antibody that recognizes phosphorylated Ser 231(pCREB). (D) CRE-Luc recording from control (CRE-Luc, open circles) and two independent
lines with Q108 expression in neurons (CRE-Luc Q108#2, filled circle, and CRE-Luc Q108#16, filled triangles). (E) Q22 expression does not reduce CRE-Luc activity.
CRE-Luc signal from control (CRE-Luc, open circle) and Q22-expressing flies (CRE-Luc Q22#433, filled circles, and CRE-Luc Q22#429, filled triangles).
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2C) or in the grossmorphology of polyQ-expressing heads (data not
shown). PolyQ expression also does not significantly affect phos-
phorylation at dCREB2 Ser-231, which is the equivalent residue to
mammalian Ser-133 (Fig. 2C). The expression of polyQ22 actually
increases CRE-Luc activity, perhaps because glutamine tracts
themselves can enhance transcription (40).
PKA Increases CREB Activity and Rescues PolyQ-Induced Lethality.
CREB-responsive transcription is involved in various cellular re-
sponses to different stimuli. It is believed that each individual
stimulus activates CREB and results in the transcription of a
different, but perhaps overlapping, subset of ‘‘downstream’’ genes.
The specificity of the target genes is thought to be at least partially
due to the details of the upstreampathways that activateCREB (for
review, see ref. 41). Therefore, we tested whether manipulating
signaling pathways that increaseCREBactivity could rescue polyQ-
induced toxicity. Transgenic flies carrying hs-PKA* (36) show
increased CREB activity in vivo at 25°C (Fig. 3A). hs-PKA*
increases the survival rate of flies that express expanded polyQ in
the nervous system at 18°C and 22°C (Fig. 3B). The increase in
survival rate with hs-PKA* is larger at 22°C than at 18°C, suggesting
that this effect depends upon the level of PKA* expression. A single
copy of hs-PKA* itself does not affect survival rate at these
conditions (the number of hs-PKA* divided by that of CyO
yields 97.9% at 18°C and 109.9% at 22°C).
We tested the effect of another kinase, MEK, using transgenic
flies carrying hs-MEK. hs-MEK flies, when raised at 22°C (Fig. 3C)
or when heat-induced (Fig. 3D) have higher CRE-Luc activity than
control flies. However, hs-MEK does not rescue polyQ-induced
lethality in flies raised at 22°C or those that receive heat shock (Fig.
3E), even though the increase in CRE-Luc activity after hs-MEK
induction is greater than that achievable with PKA (compare Fig.
3 C andD). The survival rate of polyQ flies that receive heat shock
is higher for all genotypes, presumably due to the ability of heat
shock itself to rescue polyQ effects (see below). A single copy of
hs-MEK itself does not affect survival rate at these conditions [the
number of hs-MEK divided by that of CyO yields 100.0% for
22°C and 92.2% for hs35°C, no significant decrease (P  0.05)].
These data suggest that certain, but not all, signaling pathways that
activate CREB can rescue polyQ toxicity.
Overexpression of Hsp70 Does Not Rescue PolyQ-Mediated Effects on
CREB Activity. Overexpression of heat-shock proteins can rescue
polyQ-induced degeneration in cellular, mouse, and Drosophila
models (20, 24–27, 29, 30, 42–44). However, it is unknown whether
this protective effect of heat-shock proteins involves reversal of
transcriptional defects. We tested whether Hsp70-mediated rescue
affected CREB activity in flies with expanded polyQ expression.
CRE-Luc activity remains depressed in flies that overexpress polyQ
and Hsp70 (Fig. 4A). However, overexpression of Hsp70 greatly
suppresses polyQ-mediated toxicity (Fig. 4B, compare polyQ and
polyQHsp70), as reported (27). Hsp70 overexpression itself does
not change CRE-Luc activity (Fig. 5, which is published as sup-
porting information on the PNAS web site).
The Hsp70- and CREB-mediated rescue of polyQ-induced le-
thality is additive (Fig. 4B). Although the CREB-mediated rescue
of lethality is quantitatively much smaller than that of Hsp70, it is
statistically significant (Fig. 4B, polyQ vs. polyQgdCREB; 2
Fig. 3. Effect of PKA and MEK on CRE-luciferase activity and polyQ-induced lethality. (A) Luciferase activity from control (CRE-Luc, open circles) and transgenic
flies with hs-PKA* (CRE-Luc PKA, filled circles). (B) Survival rates for flies with (polyQPKA, filled bars) or without hs-PKA* (polyQ, open bars), raised at 18°C or
22°C. (C) Luciferase signal from control flies (CRE-Luc, open circles) and that from flies with hs-MEK (CRE-Luc MEK, filled circles). (D) Luciferase signal from the
control (CRE-Luc hs, open circles) or hs-MEK (CRE-Luc MEK hs, filled circles) flies that were both exposed to heat shock. (E) Survival rates for the flies with
(polyQMEK, filled bars) or without (polyQ, open bars) the hs-MEK transgene when they were raised at 22°C (22°C) or raised at 22°C and heat-shocked at 35°C
for 30 min every day (hs35°C).
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value of 62.36,P 0.000005).When an additional copy of gdCREB
was added to flies containing polyQHsp70, there was further
significant rescue (polyQHsp70 vs. polyQgdCREBHsp70; 2
value 13.4, P  0.0005). The combined rescue achieved with
gdCREBHsp70 is greater than the sum of their individual effects,
suggesting that the effect of gdCREBandHsp70may be synergistic.
Motor defects are commonly seen inHuntington’s disease.When
polyQ-containing transgenic flies are assayed in a simple locomotor
assay, the transgenic flies show a severe decrease in activity (Fig.
4C). In this assay, the gdCREB transgene does not rescue polyQ-
mediated locomotor dysfunction, but overexpressed Hsp70 is able
to partially rescue. However, similar to the rescue of lethality,
gdCREB and Hsp70 additively rescue when cooverexpressed (Fig.
4C, asterisks), and this suppression ismore dramatic as the flies age.
Collectively, these results demonstrate that overexpression of
Hsp70 is not sufficient to reverse decreases in dCREB2 activity, and
that Hsp70 and dCREB2 can additively rescue polyQ-induced
toxicity.
Discussion
Accumulating evidence indicates that transcriptional dysregulation
is involved in the pathogenesis of polyglutamine diseases (for
review, see ref. 4). Here, we have shown that CREB is involved in
polyQ-mediated toxicity in Drosophila neurons. A heterozygous
mutation in the dCREB2 gene decreases the survival rate of flies
when expanded polyQ are expressed. An additional genomic copy
of dCREB2 slightly but significantly rescues this toxicity. Expression
of the expanded polyQ-containing peptides in neurons attenuates
CREB-responsive transcriptionmeasured using an in vivo reporter.
Taken together, these results clearly demonstrate that part of the
polyQ-induced lethality can be attributed to inhibition of CREB-
mediated transcription.
A number of reports have shown that expression of polyQ in cell
culture models attenuates CREB activity (5, 6, 8, 11–13, 45), and a
knock-in of 109 CAG repeats in mouse htt (HdhQ111) has been
reported to interfere with phosphorylation of CREB and the levels
of brain-derived neurotrophic factor mRNA in the striatum (17).
Our results are consistent with these reports. Recently, Obrietan
and Hoyt (18) reported that phosphorylation of CREB and CRE-
reporter activity was enhanced in mice carrying a transgene that
codes for an exon 1 of htt with150 glutamine repeat (R62mice).
One of the possible explanations for these conflicting results may
be that CREB is activated by secondary cellular responses against
polyQ toxicity. Various cellular responses, including ischemia (46,
47), oxidative stress (48), or excitotoxicity (49), can activate CREB.
In the R62 mouse, CREB activity was tested at a relatively late
stage (11 weeks) in the degenerative process. Another possibility is
that the increase in CREB activity is due to overexpression of htt
exon 1 residues that flank the polyQ stretch. Finally, it is possible
that the exact protein context that contains the polyQ stretch may
contribute to the observed differences.
In cellular and mouse models of Huntington’s disease, the
cAMP-PKA pathway and the phosphorylation on CREB of Ser-
133 is decreased (12, 17). In the fly model described here, there was
not a significant change in the phosphorylation level of Ser-231, the
fly equivalent to Ser-133 (Fig. 2C). This could be due to differences
in the regulatory mechanisms controlling mammalian and fly
CREBs. In contrast to mammalian CREB whose activity is mostly
correlatedwith the phosphorylation level of Ser-133, a large portion
of dCREB2 exists with Ser-231 in a phosphorylated state, suggest-
ing that other mechanisms must be important in regulating its
activity (38). Alternatively, polyQ in this fly model is overexpressed
as a peptide, whereas other studies have used polyQ runs in the
context of htt protein residues surrounding the expansion. Because
protein context plays an important role in the toxicity of polyQ
protein (50), and it is likely there are protein context-dependent and
independent changes in transcriptional profile in various polyQ
diseases (51, 52), it is important to investigate the effect of each
protein context on dysregulation of CREB-mediated transcription.
It is believed that polyQ can exist in several physical states,
including as monomeric random coils, an oligomeric  sheet form
and an SDS-insoluble large aggregate of amyloid fibrils (for review,
ref. 53). Overexpression of Hsp70 has been reported to modify the
conformation of polyQ proteins before aggregation or to increase
Fig. 4. CREB and Hsp70 additively suppress polyQ-induced toxicity. (A)
Overexpression of Hsp70 does not rescue CRE-Luc activity in polyQ-expressing
flies. Luciferase activity from control flies (CRE-Luc, open circles), flies with
Q108 expression (CRE-Luc polyQ, filled circles), and flies with Hsp70 and Q108
expression in neurons (CRE-Luc polyQHsp70, filled triangles). (B) The pro-
tective effect of Hsp70 and dCREB2 against Q108-mediated lethality are
additive. The survival rates for the flies with polyQ only, polyQ plus an extra
copy of dCREB2 (polyQgdCREB), polyQ plus Hsp70 (polyQHsp70), and
polyQ plus both gdCREB and Hsp70 (polyQgdCREBHsp70) are shown.
There is a significant difference between polyQ and polyQgdCREB, polyQ
and polyQHsp70, and polyQHsp70 and polyQgdCREBHsp70 [2 value
62.36, 15.90, and 13.41, respectively; P  0.0005 (asterisks)]. (C) gdCREB and
Hsp70 additively suppress polyQ-mediated defects in the climbing assay. The
climbing assay is shown for wild-type control flies and flies that overexpress
Hsp70, polyQ, polyQgdCREB, polyQHsp70, or polyQHsp70gdCREB. As-
terisks indicate significant differences between polyQHsp70 and
polyQHsp70gdCREB (P  0.05 with Student’s t test).
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the solubility of aggregates (54–59). Transcriptional cofactors have
been reported to interact with expanded polyQ (9, 14) or can be
sequestered into inclusions (5–8). Recently, Schaffar et al. (60)
reported that an htt fragment with expanded polyQ undergoes a
conformational change before oligomerization and inhibition of
TATA box-binding protein to bind DNA. In vitro, Hsp7040 is able
to reverse this inhibition (60).We found that Hsp70 overexpression
does not reverse polyQ inhibition of CREB-mediated transcription
(Fig. 4A). One possible interpretation of these results is that there
is a pool of toxic polyQ that does not interact with Hsp70.
Alternatively, Hsp70 interaction with polyQ may not be sufficient
to restore CREB’s transcriptional activity.
Conclusion
We have demonstrated that CREB can partially reverse polyQ-
mediated toxicity, and that the protective effects of CREB and
Hsp70 are additive. Targeting multiple pathways may be required
to cure polyglutamine diseases. Hsp70 overexpression has modest
effects in several animal models of polyglutamine disease (29, 30,
42–44, 59), and dysregulation of CREB-mediated transcription
might contribute to the remaining dysfunction. Recently, Agrawal
et al. (61) showed that geladanamycin, an enhancer of Hsp70
activity, and an histone deacetylase inhibitor additively rescue
toxicity induced by mutant htt exon 1 inDrosophila, supporting our
conclusion. It is reasonable that pharmacological enhancement of
CREB activity through specific pathway(s), or augmentation of
CREB downstream genes, might ameliorate the dysfunctional
effects of polyQ expansion. Drosophila may be a useful system to
search for such modifiers, because many functions of CREB,
including memory formation and circadian rhythms, are conserved
in flies (35, 62, 63).
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